source
- Novartis withdraws EU filing for Pluvicto label expansion into early-stage prostate cancerNovartis announced it has pulled its application to the European Medicines Agency to extend the label of its radioligand therapy Pluvicto for use in earlier stages of prostate cancer. The move com…
- Lilly shares slide as Foundayo prescriptions lag expectations, while Novo's Wegovy gains momentumEli Lilly's stock fell nearly 5% after the latest weekly prescription count for its obesity drug Foundayo missed analysts' expectations. IQVIA data showed U.S. prescriptions for Foundayo reached 3…